Novastan: Began a 750-patient Phase II trial. The primary end point is a composite of death and adverse cardiac events; secondary end point is patency after 90

Texas Biotechnology Corp. (TXB), Houston Product: Novastan ( argatroban) synthetic small molecule inhibitor of thrombin Indication: An alternative to heparin for adjunct use with streptokinase in acu...